0QOI.L

Newron Pharmaceuticals S.p.A. [0QOI.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0QOI.L Stock Summary

Top 10 Correlated ETFs

0QOI.L

Top 10 Correlated Stocks

0QOI.L

In the News

0QOI.L Financial details

Company Rating
-
Market Cap
142.52M
Income
-15.51M
Revenue
8.6M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
19 Sep 2024
P/E
-8.86
Forward P/E
-
PEG
-
P/S
15.37
P/B
-6.71
P/C
-
P/FCF
-12.16
Quick Ratio
1.14
Current Ratio
1.45
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.87
EPS next Y
-
EPS next Q
-
EPS this Y
11.49%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
0.42%
Revenue last 5Y
5.89%
Revenue Q/Q
-1.57%
EPS Q/Q
-
-
-
-
-
SMA20
-16.95%
SMA50
-29.35%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
90%
ROC
-0.76%
Gross Margin
100%
Oper. Margin
-127%
Profit Margin
-180%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.12-10.39992
52W High
-29.5%
52W Low
+76.25%
RSI
46.02
Rel Volume
-
Avg Volume
4.22K
Volume
Perf Week
7.31%
Perf Month
-14.23%
Perf Quarter
-
Perf Half Y
-14.65%
-
-
-
-
Beta
0.703
-
-
Volatility
0.22%, 0.87%
Prev Close
-2.08%
Price
7.05
Change
-2.08%

Something similar

Top by Market Cap
ABEA.DE
0YXG.L
AMZ.DE
META
M&M.NS
Top Correlated ETFs
EHE.TO
Top Correlated Stocks
0QKA.L
001470.KS
0IWU.L
AGSTRA.NS
IOB.NS
Similar Market Cap
IPU.L
DVAL
FTV.L
PYR.TO
E15G.DE

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 4.22K
  • Market Capitalization 142.52M
  • Employee 22
  • CEO Mr. Stefan Weber
  • Headquarters Bresso,MI,IT
  • IPO Date 2014-06-17
  • Website https://www.newron.com

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.